Top > Search of International Patents > BIOMARKER FOR ALZHEIMER’S DISEASE

BIOMARKER FOR ALZHEIMER’S DISEASE

Foreign code F190009757
File No. S2017-0642-C0
Posted date May 7, 2019
Country WIPO
International application number 2018JP018849
International publication number WO 2018221212
Date of international filing May 16, 2018
Date of international publication Dec 6, 2018
Priority data
  • P2017-108766 (May 31, 2017) JP
Title BIOMARKER FOR ALZHEIMER’S DISEASE
Abstract The present invention addresses the problem of providing a marker and an application thereof useful for early diagnosis or differentiation of Alzheimer’s disease. Provided is a biomarker for Alzheimer’s disease, comprising a blood-borne flotillin.
Outline of related art and contending technology BACKGROUND ART
Consisting of the senile plaques in the brain to the deposition of amyloid beta protein, Alzheimer's disease (hereinafter, abbreviated as' AD ' may be) of the pathological observations and the most representative, or the deposition of amyloid formation of the polymer to cause the onset of AD are considered. Amyloid beta (A β) metabolism is therefore (production, polymer formation, as well as decomposition, removing) the adjustment of the prevention of a disease, is considered to be the target of treatment, therapeutic drug development has been performed. According to a recent study, 20 years or more before the onset of AD A β aggregates form of senile plaques were deposited at the beginning, at the onset of a brain plaques is already present in a range becomes clear. (Tau) then the tau protein aggregates the neurofibrillary tangles as a main component and will appear, mild cognitive impairment (Mild Cognitive Impairments; MCI) via a developing dementia is considered. Receives such results of studies, the National Institute on Aging (NIA; Alzheimer's disease Society National Institute on Aging) diagnostic criteria and a revised version of the year 2011, or not brain pathology condition change step of the 'before the onset of Alzheimer's disease (Preclinical AD) ' proposed (Non-Patent Document 1) have been invented. In addition, such as amyloid vaccine therapy treatment is the root to the target, after the onset of the effect to be limited to the invention will become apparent, senile plaques is already completed after the onset of amyloid pathology progresses than be treated prior to the onset is considered to be in. Under such a background, using PET image inspection or cerebrospinal fluid such as amyloid imaging method, the AD and mild cognitive impairment (MCI) prior to the onset of treatment and diagnostic stage is attempted and made an attempt, the stage of the possible in the art. However, with invasive examination of the cerebrospinal fluid, generally in the office or hospital is difficult. In addition, the device may be expensive and reagent PET, in addition to the possibility of radiation damage cannot be denied. From such a background, a more simple inexpensive small and minimally invasive diagnostic method has been expected development. On the other hand, other dementia Alzheimer's dementia is, Lewy body dementia, vascular dementia, frontotemporal dementia (FTD) type and the like, suitable for the prevention/treatment is necessary for the differential diagnosis. In fact, such as a depression in the elderly patient, Alzheimer's dementia often requires discrimination of the case.
On the other hand, in the brain that exosomes A β protein to present, to serve to remove the reported findings, in the development of AD role of exosomes is attracting attention. However, for the change in the level of exosomes AD was completely unknown. In this regard, studies of the inventors of the present invention group, in the cells treated with Aβ1-42, the secretion of exosomes reported phenomenon is significantly reduced (non-patent document 2).
Scope of claims (In Japanese)請求の範囲 [請求項1]
 血中フロチリンからなる、アルツハイマー病バイオマーカー。

[請求項2]
 請求項1に記載のバイオマーカーのレベルを指標とした、アルツハイマー病の検査法。

[請求項3]
 アルツハイマー病の早期検出のための検査法である、請求項2に記載の検査法。

[請求項4]
 以下のステップ(1)及び(2)を含む、請求項3に記載の検査法:
 (1)血液検体中の前記バイオマーカーを検出するステップ;
 (2)検出結果に基づき、アルツハイマー病の発症可能性又はアルツハイマー病の罹患の有無を判定するステップ。

[請求項5]
 アルツハイマー病の鑑別のための検査法である、請求項2に記載の検査法。

[請求項6]
 アルツハイマー型認知症以外の認知症との鑑別に用いられる、請求項5に記載の検査法。

[請求項7]
 アルツハイマー型認知症以外の認知症が、脳血管型認知症、レビー小体型認知症又は前頭側頭型認知症である、請求項6に記載の検査法。

[請求項8]
 以下のステップ(1)及び(2)を含む、請求項5~7のいずれか一項に記載の検査法:
 (1)血液検体中の前記バイオマーカーを検出するステップ;
 (2)検出結果に基づき、罹患する疾患がアルツハイマー病であるか否かを判定するステップ。

[請求項9]
 前記血液検体が血清又は血漿である、請求項4又は8に記載の検査法。

[請求項10]
 請求項1に記載のバイオマーカーに特異的結合性を有する物質からなる、アルツハイマー病検査試薬。

[請求項11]
 前記物質が抗フロチリン抗体である、請求項10に記載のアルツハイマー病検査試薬。

[請求項12]
 請求項10又は11に記載のアルツハイマー病検査試薬を含む、アルツハイマー病検査キット。

  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY
  • NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY
  • Inventor
  • MICHIKAWA Makoto
  • AKATSU Hiroyasu
  • ABDULLAH Mohammad
  • MATSUBARA Etsuro
  • KIMURA Noriyuki
IPC(International Patent Classification)
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close